ICRA downgrades Hikal’s long- and short-term ratings to A (Stable) and A2+ from A+ (Stable) and A1, citing USFDA action and sector pressures; recovery in H2 FY2026 remains watchful.
AI Assistant
Hikal Ltd
2025
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.